What Is the EU IVDR Regulation? Key Requirements for IVD Devices
The In Vitro Diagnostic Regulation (IVDR) is the European Union’s framework for regulating tests that examine samples such as blood, tissue, or saliva. It affects manufacturers, importers, distributors, laboratories, and other organizations that place in vitro diagnostic devices on the EU market. Understanding the IVDR’s risk-based classification, evidence, conformity assessment, and post-market requirements is important for anyone working with diagnostic products, including U.S. companies that sell them in Europe.
The IVDR classifies IVDs according to risk to individuals and public health. Classification is based on the device’s intended purpose and the rules in Annex VIII. A manufacturer must document why a device belongs in a particular class; a product’s former classification under the directive does not automatically carry over.
| IVDR class | General risk profile | Examples or typical areas |
|---|---|---|
| Class A | Low individual and public-health risk | Some instruments, specimen receptacles, and general laboratory products |
| Class B | Moderate individual risk or low public-health risk | Many routine diagnostic tests |
| Class C | High individual risk or moderate public-health risk | Tests related to cancer, genetic testing, or certain infectious diseases |
| Class D | High public-health risk or very high individual risk | Selected tests for serious communicable agents or blood-transfusion safety |
These descriptions are general, not classification decisions. The exact class depends on the applicable rule and the manufacturer’s stated purpose. For example, a test for the same analyte may be classified differently depending on whether it is intended for screening, diagnosis, donor testing, or treatment decisions. Classification should be determined and justified before selecting the conformity-assessment route.
Key IVDR Requirements for Manufacturers
Quality management and risk management
Manufacturers must establish, document, implement, and maintain a quality management system appropriate to their organization and devices. The system should cover regulatory strategy, design and development, production, supplier controls, documentation, corrective actions, and post-market activities. The regulation does not simply require a certificate; the manufacturer remains responsible for meeting applicable legal requirements.
Risk management must continue throughout the device life cycle. Manufacturers identify hazards, estimate and evaluate risks, implement controls, and review whether those controls remain effective as new information becomes available. Risk management is linked to design, performance evaluation, manufacturing, and post-market surveillance rather than treated as a one-time exercise.
Technical documentation
Manufacturers must prepare and maintain technical documentation demonstrating conformity with the IVDR. Annexes II and III describe the core documentation and post-market surveillance documentation. The file typically includes the device description and intended purpose, design and manufacturing information, risk analysis, performance evidence, labeling, and the plan for post-market monitoring.
Documentation must be sufficiently clear and complete for a notified body or competent authority to assess the device. It should be kept current when design, manufacturing, intended purpose, or relevant evidence changes. Manufacturers must retain documentation for the periods specified in the regulation, generally at least 10 years after the last device covered by the declaration of conformity is placed on the market, and 15 years for implantable devices.
Performance evaluation and evidence
IVDR performance evaluation considers three connected elements: scientific validity, analytical performance, and clinical performance. Scientific validity concerns the relationship between the analyte and the clinical condition or physiological state. Analytical performance concerns the device’s ability to detect or measure the analyte accurately. Clinical performance concerns how well the result relates to the relevant clinical condition or state in the intended population and setting.
Evidence is documented in a performance evaluation report and supported by appropriate data. Depending on the device and the evidence available, manufacturers may use scientific literature, analytical or clinical performance studies, and other relevant sources. A performance evaluation is maintained throughout the device life cycle, with new information considered through post-market performance follow-up (PMPF).
Performance studies involving human subjects must comply with the IVDR’s applicable requirements, including provisions for informed consent, ethics review, protection of participants, and reporting. The exact obligations depend on the type of study and whether the device is used within its intended purpose or to establish performance.
Conformity assessment and CE marking
Before an IVD is placed on the EU market, its manufacturer must demonstrate conformity with the applicable general safety and performance requirements and follow the relevant conformity-assessment procedure. Class A devices that are not sterile can generally be self-declared, while sterile Class A devices and Class B, C, and D devices generally require notified-body involvement. The applicable route varies by class and device type.
After conformity is established, the manufacturer draws up an EU declaration of conformity and affixes the CE marking. When a notified body participates, its four-digit identification number appears alongside the CE mark. CE marking indicates conformity with applicable EU requirements; it is not an endorsement by the European Commission or a guarantee that a test is appropriate for every use.
Authorized representatives and economic operators
A manufacturer established outside the EU must appoint an EU authorized representative in writing before placing devices on the EU market. The representative has defined regulatory responsibilities and must verify specified manufacturer obligations. It is not simply a local sales agent, and its role does not transfer the manufacturer’s overall responsibility for device compliance.
Importers and distributors also have obligations. These include checking relevant conformity and labeling information, preserving required storage and transport conditions, maintaining traceability, and cooperating with authorities or corrective actions. Economic operators must be able to identify, as applicable, who supplied a device and to whom it was supplied.
Labeling, UDI, and registration
IVDR labeling and instructions for use must provide information needed to identify the device and use it safely for its intended purpose. Requirements vary by product and can include the manufacturer’s details, intended purpose, warnings, limitations, storage conditions, and information on performance. Instructions and other user-facing information must meet applicable language requirements in the countries where the device is made available.
The regulation establishes a Unique Device Identification (UDI) system. A UDI helps identify devices and supports traceability, safety monitoring, and corrective action. Manufacturers assign the relevant UDI and place it on the label or packaging as required. They also have registration and data-submission responsibilities under the IVDR’s electronic systems, subject to the applicable implementation arrangements.
Post-Market Surveillance and Vigilance
Compliance continues after a device enters the market. Each manufacturer must create a post-market surveillance (PMS) system that actively and systematically gathers information about device quality, performance, and safety. The information is analyzed to identify trends, confirm that risks remain acceptable, and determine whether corrective or preventive action is needed.
Manufacturers document PMS activities in a PMS report for Class A and B devices, or a periodic safety update report (PSUR) for Class C and D devices. PSURs are updated at least annually for Class C and D devices; the IVDR sets a less frequent minimum update interval for Class B devices. The exact reporting obligations and availability to authorities or notified bodies depend on the device class and applicable provisions.
Manufacturers must also operate vigilance processes. Serious incidents and field safety corrective actions are reportable under the regulation, with timing dependent on the seriousness and circumstances. Field safety notices communicate relevant corrective actions to users. PMS and vigilance information can lead to changes in labeling, risk controls, performance evaluation, or the device itself.
Transition Timelines and Legacy Devices
The IVDR has applied since May 26, 2022. Later amendments introduced extended transition periods for certain devices that had been covered by a valid directive certificate or a declaration of conformity under the former rules. The extended dates are not blanket permission to continue selling every legacy device without meeting IVDR conditions.
Under the amended transition framework, the main end dates are December 31, 2027, for eligible Class D devices; December 31, 2028, for eligible Class C devices; and December 31, 2029, for eligible Class B devices and sterile Class A devices. Eligibility depends on conditions in the regulation, which include continued compliance with the former directive, no significant change in design or intended purpose, and the manufacturer establishing an IVDR-compliant quality management system and applying to a notified body by specified deadlines.
Deadlines and eligibility can depend on a device’s status and the specific transitional provision. Manufacturers should consult the current consolidated text of the regulation and guidance from the European Commission and relevant authorities rather than assume that an old certificate alone permits continued market access.
Practical Compliance Steps
Organizations preparing for IVDR compliance can use a structured plan to identify gaps and assign ownership:
- Confirm scope and intended purpose. Document what the product is, how it is used, and the claims made in labeling and promotional materials.
- Determine the IVDR class. Apply Annex VIII classification rules and retain a rationale for the result.
- Choose the conformity-assessment route. Identify whether a notified body is required and confirm that it is designated for the relevant device scope.
- Build the evidence file. Align risk management, technical documentation, performance evaluation, and labeling with the device’s intended purpose.
- Establish operating processes. Put quality management, UDI, registration, supplier oversight, PMS, PMPF, and vigilance procedures in place.
- Plan for market changes. Track regulatory updates, notified-body capacity, transitional deadlines, and changes to the device or its claims.
For U.S. businesses, an EU launch plan should be coordinated across regulatory, quality, clinical, labeling, and commercial teams. The IVDR’s requirements may affect development plans, evidence generation, packaging, and distribution arrangements. Regulatory counsel or a qualified EU regulatory specialist can help interpret requirements for products with unusual intended purposes or borderline classifications.
Where to Check Official IVDR Information
The primary legal source is Regulation (EU) 2017/746 on EUR-Lex. Its amendments include Regulation (EU) 2022/112, Regulation (EU) 2023/607, and Regulation (EU) 2026/1860. The European Commission’s IVD medical devices page provides related guidance and implementation information.
Because the IVDR is detailed and amendments may affect transition arrangements or implementation, organizations should verify the latest official text and guidance before making market-access decisions. The regulation’s central principle remains clear: the manufacturer must substantiate an IVD’s performance and safety, follow the correct conformity route, and continue monitoring it after market placement.